公开(公告)号：DE69838479D1

公开(公告)日：2007-11-08

申请号：DE69838479

申请日：1998-05-08

Applicant: MEDTRONIC INC

Inventor： BENZ MICHAEL ERIC ,  BONNEMA KELVIN ,  DIDOMENICO EDWARD ,  HOBOT CHRISTOPHER M ,  MILLER DAVID L

IPC: A61L27/00 ,  A61L27/18 ,  A61L27/34 ,  A61L29/06 ,  A61L29/08 ,  A61L31/06 ,  A61L31/10 ,  A61L33/06

公开(公告)号：AU2003270704A1

公开(公告)日：2004-04-08

申请号：AU2003270704

申请日：2003-09-16

Applicant: MEDTRONIC INC

Inventor： SPARER RANDALL V ,  BENZ MICHAEL E ,  HOBOT CHRISTOPHER M ,  BONNEMA KELVIN

IPC: A61L27/00 ,  A61L31/00 ,  A61M1/10 ,  C08G18/10 ,  C08G18/38 ,  C08G18/64 ,  C08G77/00 ,  C08G77/60 ,  C08G85/00

Abstract: Polymers that include silane-containing groups in soft segments, and optionally urethane groups, as well as medical devices and methods for making such compounds.

公开(公告)号：CA2499344A1

公开(公告)日：2004-04-01

申请号：CA2499344

申请日：2003-09-16

Applicant: MEDTRONIC INC

Inventor： TAPSAK MARK A ,  PEARSON DAVID A ,  SPARER RANDALL A ,  MILLER DAVID L ,  DIDOMENICO EDWARD ,  HOBOT CHRISTOPHER M ,  BENZ MICHAEL E

IPC: A61L27/18 ,  C08G18/61 ,  C08G77/50 ,  A61L31/00

Abstract: Compounds that include silicon-containing groups, and optionally urethane groups, urea groups, or combinations thereof (i.e., polyurethanes, polyureas , or polyurethane-ureas), as well as materials and methods for making such compounds.

公开(公告)号：AU2003265446A1

公开(公告)日：2004-02-25

申请号：AU2003265446

申请日：2003-08-13

Applicant: MEDTRONIC INC

Inventor： DANG KIEM ,  SPARER RANDALL V ,  HOBOT CHRISTOPHER M ,  LYU SUPING

IPC: A61L27/26 ,  A61L27/34 ,  A61L27/54 ,  A61L31/04 ,  A61L31/10 ,  A61L31/16

Abstract: The present invention provides active agent delivery systems for use in medical devices, wherein the active agent delivery systems include an active agent and a hydrophilic miscible polymer blend that includes an active agent and a miscible polymer blend comprising a hydrophilic polymer (preferably, a polyurethane) and a second polymer having a different swellability in water at 37° C.

公开(公告)号：AU2002359388A1

公开(公告)日：2003-05-26

申请号：AU2002359388

申请日：2002-11-13

Applicant: MEDTRONIC INC

Inventor： SCHWENDEMAN JOHN E ,  DIDOMENICO EDWARD ,  WAGENER KENNETH B ,  HOBOT CHRISTOPHER M ,  BENZ MICHAEL E

IPC: A61L27/18 ,  C08F236/20 ,  C08G18/62 ,  A61L29/00

公开(公告)号：DE68928020T2

公开(公告)日：1997-11-20

申请号：DE68928020

申请日：1989-09-29

Applicant: MEDTRONIC INC

Inventor： COURY ARTHUR J ,  HOBOT CHRISTOPHER M

IPC: C07C271/16 ,  C08G18/32 ,  C08G18/38 ,  C08G18/50 ,  C08G18/61 ,  C08G71/04 ,  C08G18/46

公开(公告)号：DE69028966D1

公开(公告)日：1996-11-28

申请号：DE69028966

申请日：1990-08-22

Applicant: MEDTRONIC INC

Inventor： DIDOMENICO EDWARD D ,  COURY ARTHUR J ,  HOBOT CHRISTOPHER M ,  DOAN PHONG D ,  STOKES KENNETH B ,  SANDSTROM RICHARD D

IPC: A61K9/00 ,  A61K9/20 ,  A61K9/70 ,  A61K47/34 ,  A61M37/00 ,  A61N1/05 ,  A61K9/22

Abstract: A cardiac pacing lead or other stimulation lead carrying a steroid compounded within a polymer matrix. The steroid is dispersed in thermoplastic or thermoset polyurethane or polyurea forming monomers or prepolymers. The mixture is then chain extended by addition of the appropriate difunctional or multifunctional isocyanate, hydroxyl or amine curing agent to form a solid polymer. The resulting formulation is molded or cast into a desired shape, and incorporated in the distal end of a medical electrical lead, adjacent to or within the electrode. In a preferred embodiment, the medical lead employs an extendable helix which is screwed into body tissue, and the polymer containing the drug takes the form of a generally dimensionally stable annular member mounted to the lead, encircling the helix.

公开(公告)号：CA1313280C

公开(公告)日：1993-01-26

申请号：CA614347

申请日：1989-09-28

Applicant: MEDTRONIC INC

Inventor： COURY ARTHUR J ,  HOBOT CHRISTOPHER M ,  CARLSON KURT

IPC: A61L27/00 ,  C08G18/10 ,  C08G18/32 ,  C08G18/38 ,  C08G18/65 ,  C08G18/66 ,  C08G18/73 ,  C08G18/75

Abstract: BIOSTABLE, SEGMENTED ALIPHATIC POLYURETHANES AND PROCESS THEREFOR Highly stable, segmented, aliphatic polyurethanes prepared by particular processes are disclosed. The segmented polyurethanes of this invention are substantially free of ester and ether linkages and are found to be particularly hydrolytically and oxidatively stable. The polyurethanes of this invention are prepared by a particular two stage process involving the formation of a prepolymer and subsequent reaction with simultaneously or sequentially added diisocyanate and diol monomers.

公开(公告)号：AU614249B2

公开(公告)日：1991-08-22

申请号：AU4142389

申请日：1989-09-14

Applicant: MEDTRONIC INC

Inventor： COURY ARTHUR J ,  HOBOT CHRISTOPHER M

IPC: C07C271/16 ,  C08G18/32 ,  C08G18/38 ,  C08G18/50 ,  C08G18/61 ,  C08G71/04 ,  C07C271/12 ,  C07D295/20 ,  C07F7/10 ,  C08G65/32

公开(公告)号：WO2009129460A4

公开(公告)日：2010-04-15

申请号：PCT/US2009040953

申请日：2009-04-17

Applicant: WARSAW ORTHOPEDIC INC ,  MEDTRONIC INC ,  ZANELLA JOHN MYERS ,  KING VANJA MARGARETA ,  HOBOT CHRISTOPHER M ,  BIGGS DANIELLE ,  SHAW KATARA ,  MCDONALD PHILLIP EDWARD ,  MCKAY WILLIAM F ,  REMSEN KATHY L

Inventor： ZANELLA JOHN MYERS ,  KING VANJA MARGARETA ,  HOBOT CHRISTOPHER M ,  BIGGS DANIELLE ,  SHAW KATARA ,  MCDONALD PHILLIP EDWARD ,  MCKAY WILLIAM F ,  REMSEN KATHY L

IPC: A61K9/00 ,  A61K9/20 ,  A61K31/4162 ,  A61K47/34

CPC classification number: A61K31/4168 ,  A61K9/0024 ,  A61K9/204 ,  A61K31/4162 ,  A61K47/34

Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract translation: 提供长时间有效的疼痛治疗。 通过在目标部位或其附近施用有效量的可乐定，可以缓解由不同来源引起的疼痛，包括但不限于脊椎间盘突出症（即坐骨神经痛），导丝术，狭窄，椎间盘源性背痛和关节疼痛，作为 以及与手术有关的疼痛。 当在生物可降解聚合物内提供适当的制剂时，这种缓解可以持续至少三天。 在一些实施方案中，缓解剂可以是至少二十五天，至少五十天，至少一百天，至少一百三十五天或至少一百八十天。